(Q41137652)

27 September 2017

1 reference

title

Gene-marking and haemopoietic stem-cell transplantation (English)

1 reference

27 September 2017

2

Rooney CM

1 reference

27 September 2017

3

Brenner MK

1 reference

27 September 2017

1

Heslop HE

1 reference

PubMed ID

8839397

27 September 2017

language of work or name

1 reference

1 December 1995

1 reference

27 September 2017

1 reference

27 September 2017

9

1 reference

27 September 2017

4

1 reference

27 September 2017

220-225

1 reference

Autologous bone marrow transplantation

27 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Autologous bone marrow transplant for children with AML in first complete remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of relapse/refractory neuroblastoma without apparent bone marrow involvement: use of marker genes to investigate the biology of marrow reconstitution

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

A phase I trial of high-dose carboplatin and etoposide with autologous marrow support for treatment of stage D neuroblastoma in first remission: use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Retroviral-Mediated Gene Transfer of Bone Marrow Cells During Autologous Bone Marrow Transplantation for Acute Leukemia. University of Indiana

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous ma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelog

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Study on Contribution of Genetically Marked Peripheral Blood Repopulating Cells to Hematopoietic Reconstitution After Transplantation. Fred Hutchinson Cancer Research Center, Seattle, Washington

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Retroviral-mediated gene transfer of CD34-enriched bone marrow and peripheral blood cells during autologous stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

A phase I study of autologous bone marrow transplantation with stem cell gene marking in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Gene transfer into hematopoietic stem cells: long-term maintenance of in vitro activated progenitors without marrow ablation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Use of marker genes to investigate the mechanism of relapse and the effect of bone marrow purging in autologous transplantation for stage D neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Donor T cells to treat EBV-associated lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Graft-versus-host reactions and bone-marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Identification of a graft versus host disease-associated human minor histocompatibility antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

Induction of anti-self-immunity to cure cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2895%2990013-6

7 January 2021

10.1016/S0268-960X(95)90013-6

Identifiers

DOI

1 reference

27 September 2017

1 reference

PubMed ID

8839397